Drug name - Daklinza

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9421192 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

US8642025 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

US8329159 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Jul, 2029

(6 years from now)

US8629171 BRISTOL-MYERS SQUIBB Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Jun, 2031

(8 years from now)

CN101778840A BRISTOL-MYERS SQUIBB Crystalline Form Of Methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-2-Pyrrolidinyl)-1H-Imidazol-5-Yl)-4-Biphenylyl)-1H-Imidazol-2-Yl)-1-Pyrrolidinyl)Carbonyl)-2-Methylpropyl)Carbamate Dihydrochloride Salt
Jul, 2021

(1 year, 2 months ago)

CN101778840B BRISTOL-MYERS SQUIBB Crystalline Form Of Methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-2-Pyrrolidinyl)-1H-Imidazol-5-Yl)-4-Biphenylyl)-1H-Imidazol-2-Yl)-1-Pyrrolidinyl)Carbonyl)-2-Methylpropyl)Carbamate Dihydrochloride Salt
Jul, 2021

(1 year, 2 months ago)

CN104447707B BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

CN104447707A BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

CN101558059A BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

CN101558059B BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitor
Aug, 2027

(4 years from now)

EP2784075A1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

EP3042901B1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

EP2784075B1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

EP3042901A1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

EP2183244A1 BRISTOL-MYERS SQUIBB Crystalline Form Of Methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-2-Pyrrolidinyl)-1H-Imidazol-5-Yl)-4-Biphenylyl)-1H-Imidazol-2-Yl)-1-Pyrrolidinyl)Carbonyl)-2-Methylpropyl)Carbamate Dihydrochloride Salt
Jul, 2028

(5 years from now)

EP2183244B1 BRISTOL-MYERS SQUIBB Crystalline Form Of Methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-2-Pyrrolidinyl)-1H-Imidazol-5-Yl)-4-Biphenylyl)-1H-Imidazol-2-Yl)-1-Pyrrolidinyl)Carbonyl)-2-Methylpropyl)Carbamate Dihydrochloride Salt
Jul, 2028

(5 years from now)

EP2049522A2 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2029

(6 years from now)

EP2049522B1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900566 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors Aug, 2027

(4 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE TABLET;ORAL Discontinued
EQ 60MG BASE TABLET;ORAL Discontinued
EQ 90MG BASE TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.